Prolonged treatment-free remission after venetoclax in combination with a hypomethylating agent in acute myeloid leukemia with inv(16)
Annals of Hematology · 10.08.2026 · 105 (11)
DOI: 10.1007/s00277-026-07237-0 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Hematology, online erschienen am 10.08.2026. Verfasst von Morgan L Shannon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Stanford Health Care, Stanford, CA, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Chromosome Inversion, Leukemia, Myeloid, Acute. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Core binding factor acute myeloid leukemia (CBF-AML)-defined by t(8;21) or inv(16) chromosomal rearrangements-is classified as favorable-risk disease per the European LeukemiaNet 2022 risk model and is typically treated with intensive chemotherapy. Patients unsuitable for intensive therapy increasingly receive hypomethylating agents plus venetoclax (HMA/ven), though CBF-AML was excluded from pivotal trials of this regimen. Furthermore, HMA/ven is typically administered as indefinite therapy in AML; however, there is increasing interest in exploring the feasibility of therapy cessation given persistent treatment-free remissions with this regimen. Here, we report the first case of sustained treatment-free remission following HMA/ven in CBF-AML. Features in this case that suggest a higher likelihood of achieving a durable treatment-free remission include inv(16) disease and rapid measurable residual disease (MRD) clearance. We summarize the current retrospective data comparing response rates of inv(16) vs. t(8;21) AML to HMA/ven: inv(16) AML consistently exhibits higher response rates compared with t(8;21) disease, although an overall survival benefit is not well established. Emerging data also suggest achieving MRD-negative complete remission after induction may predict more durable outcomes. This case provides proof-of-concept that carefully selected CBF-AML patients achieving sustained MRD-negative remission with HMA/ven can successfully discontinue therapy. Prospective evaluation of HMA/ven in unfit CBF-AML patients, weighed against dose-attenuated intensive chemotherapy, is needed to define its role and optimal duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Stanford Health Care, Stanford, CA, USA.
- Division of Hematology, Department of Medicine, Stanford Health Care, Stanford, CA, USA.
- Division of Hematology, Department of Medicine, Stanford Health Care, Stanford, CA, USA. gmannis@stanford.edu.
Zitieren
APA
Shannon, M. L., Wallace, J., Kuo, A., & Mannis, G. N. (2026). Prolonged treatment-free remission after venetoclax in combination with a hypomethylating agent in acute myeloid leukemia with inv(16). Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07237-0
Vancouver
Shannon ML, Wallace J, Kuo A, Mannis GN. Prolonged treatment-free remission after venetoclax in combination with a hypomethylating agent in acute myeloid leukemia with inv(16). Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07237-0
BibTeX
@article{Shannon2026,
author = {Shannon, Morgan L and Wallace, Jared and Kuo, Amy and Mannis, Gabriel N},
title = {Prolonged treatment-free remission after venetoclax in combination with a hypomethylating agent in acute myeloid leukemia with inv(16)},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {11},
doi = {10.1007/s00277-026-07237-0}
}
EUVIMED